Drugs / AVD-104
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06181227 | Nov 2023 → Apr 2024 | diabetic macular edema | Aviceda Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05839041 | May 2023 → Apr 2026 overdue | degeneration of macula and posterior pole | Aviceda Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVD-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06181227 ↗ |
| Modality | Other / unclassified | “a novel glyco-mimetic nanoparticle” NCT06181227 ↗ |
| Route | Intravitreal | “intravitreal injections” NCT06181227 ↗ |